Vertex Pharmaceuticals stock rises 1.13% and outperforms competitors
Updated
Updated · MarketWatch · May 8
Vertex Pharmaceuticals stock rises 1.13% and outperforms competitors
5 articles · Updated · MarketWatch · May 8
Shares closed at $429.82 on Friday as the S&P 500 gained 0.84% to 7,398.93 and the Dow Jones Industrial Average edged up 0.02% to 49,609.16.
Vertex ended 15.38% below its 52-week high of $507.92 reached on 10 March. AbbVie fell 0.57%, while Krystal Biotech and Arcturus Therapeutics rose 3.04% and 3.60% respectively.
Trading volume was 952,802 shares, 342,318 below the stock's 50-day average of 1.3 million, indicating lighter-than-usual activity despite the broader market's positive session.
If Vertex's future is so bright, why are top executives selling millions in stock?
How will Vertex balance profits with patient access for its revolutionary, high-cost gene therapies?
Can Vertex replicate its cystic fibrosis monopoly in more crowded and competitive drug markets?